Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical ...
Apr 4, 2012
0
0
(Medical Xpress)—Type 2 diabetes (T2D) and cardiovascular disease (CVD) appear to have a lot in common. They share risk factors such as obesity and they often occur together. If they also share the same genetic underpinings, ...
Nov 4, 2014
0
0
In a study recently published in Cancer Research, Van Andel Research Institute (VARI) researchers found a protein that could help predict the spread of the head and neck cancer nasopharyngeal carcinoma (NPC); this protein ...
Jun 14, 2011
0
0
(Medical Xpress)—Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for treating ...
Aug 20, 2013
1
0
One of the most common brain cancers in children, Sonic Hedgehog (SHH) medulloblastoma, also is one of the more survivable for most kids. Unfortunately, for a subset of patients the cancer resists treatment and relapses with ...
Aug 29, 2019
0
102
Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.
Jul 6, 2011
0
0
Cancer cells circulating in the blood carry newly identified proteins that could be screened to improve prognostic tests and suggest targets for therapies, report scientists at the Duke Cancer Institute.
Jun 27, 2011
0
0
A novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers and one long considered "undruggable"—shrank tumors in most patients in a clinical trial with manageable side ...
Oct 25, 2020
0
17
Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, ...
Nov 13, 2011
0
0
Researchers report that a drug targeting the cancer-causing gene MYC inhibits the function of the gene in a phase I clinical trial. Until now, no other drug has been able to do this safely and effectively.
Oct 26, 2022
0
10
